BI 2536

Name: BI 2536
Brand: Selleck Chemicals
SKU: S1109
Rating: 5 (200 reviews)

For research use only.

Catalog No.S1109

200 publications

CAS No. 755038-02-9

BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2.

Selleck's BI 2536 has been cited by 200 publications

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Science, 2015, 13;347(6227):aaa2630.

PubMed: 25636800 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 11;147(4):853-67.

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30774-7

PubMed: 33248027 ( click the link to review the publication )

Mol Cell, 2020, 10.1016/j.molcel.2020.01.023

PubMed: 32035037 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

Autophagy, 2020, 1-17

PubMed: 33315519 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e201910148

PubMed: 33053167 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6):e201910019

PubMed: 32271878 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3605-3615.e5

PubMed: 32187533 ( click the link to review the publication )

Cell Death Differ, 2020, 19

PubMed: 32203171 ( click the link to review the publication )

Oncogene, 2020, 39(15):3145-3162

PubMed: 32060423 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cells, 2020, 9(9)E2126

PubMed: 32961751 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(3):350-362

PubMed: 32017920 ( click the link to review the publication )

ACS Chem Biol, 2020, 20;15(3):669-674

PubMed: 32004428 ( click the link to review the publication )
J Cell Sci, 2020, 2;jcs.244442

PubMed: 32487663 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(4):833-839

PubMed: 31708096 ( click the link to review the publication )

DNA Cell Biol, 2020, 10.1089/dna.2019.5002

PubMed: 32182129 ( click the link to review the publication )

Antivir Ther, 2020, 25(3):151-162

PubMed: 32496211 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12327

PubMed: 32704044 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947732 ( click the link to review the publication )

J Cancer, 2020, 11(11):3274-3287

PubMed: 32231733 ( click the link to review the publication )

Neuroreport, 2020, 31(11):787-797

PubMed: 32568772 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):1824

PubMed: 32645997 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Curr Biol, 2019, 29(7):1232-1242.e5

PubMed: 30905608 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )
FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31511529 ( click the link to review the publication )

Front Genet, 2019, 10:411

PubMed: 31130988 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Mol Reprod Dev, 2019, 86(8):972-983

PubMed: 31136049 ( click the link to review the publication )

Elife, 2019, 8e47097

PubMed: 31393265 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Elife, 2018, 7:e36739

PubMed: 29897330 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )
Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197165

PubMed: 29746542 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:5703-5713

PubMed: 30254463 ( click the link to review the publication )

J Oncol, 2018, 2018:3979527

PubMed: 30631355 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Br J Cancer, 2018, 118(6):e13

PubMed: 29438360 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28994651 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(8):1017-1028

PubMed: 28807782 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Curr Biol, 2017, 27(10):1477-1484

PubMed: 28479321 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Cell Physiol, 2017, 232(10):2818-2828

PubMed: 27861885 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28387346 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8629

PubMed: 28819179 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )
Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170650

PubMed: 28125646 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005860

PubMed: 27579920 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15215-29

PubMed: 26934655 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )
Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Genes Dev, 2015, 29(18):1969-79

PubMed: 26385965 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29617-28

PubMed: 26468278 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9327-40

PubMed: 25871386 ( click the link to review the publication )
Oncotarget, 2015, 6(33):34475-93

PubMed: 26439686 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(23):3685-97

PubMed: 25483079 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8379-92

PubMed: 25268741 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Dev Cell, 2013, 25(6):555-71

PubMed: 23769972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )
Genes Dev, 2013, 27(20):2259-73

PubMed: 24142876 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 16):3627-37

PubMed: 23750008 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

Cell Cycle, 2013, 12(14):2255-65

PubMed: 24067368 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

Biol Open, 2013, 2(10):1022-31

PubMed: 24167712 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6667-78

PubMed: 23983103 ( click the link to review the publication )

Cell Cycle, 2013, 12(9):1340-51

PubMed: 23574746 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(10):e46546

PubMed: 23056340 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )
Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

c-Myc ^[3] ()	PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)	BRD4 ^[3] (Cell-free assay)
	0.83 nM	3.5 nM	9.0 nM	37 nM(Kd)

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXwbINTUUN3ME2wMlAxPzd4IN88US=>	MlX1V2FPT0WU
ACN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rUNGlEPTB;MD6wNFg1OyEQvF2=	MX3TRW5ITVJ?
TE-8	NUHDcG55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfzNGZKSzVyPUCuNFA6PDFizszN	NF\TVYlUSU6JRWK=
LC-2-ad	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES4bZBKSzVyPUCuNFExQTNizszN	Mn\GV2FPT0WU
ALL-PO	M2f3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS4VmRZUUN3ME2wMlAyOyEQvF2=	MnPqV2FPT0WU
EW-16	M4f1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHpN2FKSzVyPUCuNFE{OzZizszN	NXSx[GE4W0GQR1XS
KM12	NHPjTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLVT\|lKUUN3ME2wMlAyOzR6IN88US=>	NH;2NWxUSU6JRWK=
GI-1	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPKN4liUUN3ME2wMlAyOzh\|IN88US=>	NXfFWo91W0GQR1XS
LS-411N	M1Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHqVFRKSzVyPUCuNFE1ODdizszN	M33mb3NCVkeHUh?=
ES8	NXvPelR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT2eJZyUUN3ME2wMlAyPDl2IN88US=>	MnHCV2FPT0WU
SNU-C2B	NVfPcGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rBWWlEPTB;MD6wNVUzPiEQvF2=	M4mzeXNCVkeHUh?=
CESS	NEHVO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\VTWM2OD1yLkCxOlAzKM7:TR?=	NHzqN\|dUSU6JRWK=
697	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml24TWM2OD1yLkCxOlY5KM7:TR?=	MUjTRW5ITVJ?
NCI-H1963	NVGyR21sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLjTWM2OD1yLkCxOlc{KM7:TR?=	MlvDV2FPT0WU
IA-LM	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jJZWlEPTB;MD6wNVY5QCEQvF2=	NWjLW3NuW0GQR1XS
SW954	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T3emlEPTB;MD6wNVcxPSEQvF2=	NWryNXBoW0GQR1XS
RL95-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTpTWM2OD1yLkCxO\|M5KM7:TR?=	M2TNeHNCVkeHUh?=
LXF-289	NXPyXFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwMEG3O{DPxE1?	NVTwSGFJW0GQR1XS
OCUB-M	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwMEG4NlYh\|ryP	NGm2U5ZUSU6JRWK=
RKO	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTBwMEG5PFch\|ryP	NYDKb3JPW0GQR1XS
LOUCY	NFnTSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXQTWM2OD1yLkCyNFUh\|ryP	MXzTRW5ITVJ?
NOS-1	NEjrOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWSwTFRTUUN3ME2wMlAzODl\|IN88US=>	MUfTRW5ITVJ?
A4-Fuk	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTBXo1yUUN3ME2wMlAzOjF6IN88US=>	NFvzSZRUSU6JRWK=
A388	M2m4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlX2TWM2OD1yLkCyNlI4KM7:TR?=	NUTTdphIW0GQR1XS
TE-9	M{XXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFf2Z4pKSzVyPUCuNFIzPjFizszN	NW\4WphuW0GQR1XS
KURAMOCHI	MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPUdZNKSzVyPUCuNFIzQDVizszN	MlLZV2FPT0WU
KALS-1	NET2SYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnmyTWM2OD1yLkCyN\|M5KM7:TR?=	NVjROYdnW0GQR1XS
HOP-62	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4S0eWlEPTB;MD6wNlQzKM7:TR?=	NGmze4pUSU6JRWK=
RPMI-8402	NFP5U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrLTWM2OD1yLkCyOVA5KM7:TR?=	M4fNb3NCVkeHUh?=
TE-1	NYnoVWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFiwPWZKSzVyPUCuNFI2OTJizszN	MojYV2FPT0WU
CCRF-CEM	NIi2VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwMEK1OFMh\|ryP	NX\QTJp2W0GQR1XS
HUTU-80	NVq5VHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jXeWlEPTB;MD6wNlYzPCEQvF2=	M1\uNnNCVkeHUh?=
NCI-H1648	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33jSWlEPTB;MD6wNlY1PyEQvF2=	MmLnV2FPT0WU
HCE-4	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTBwMEK2PFIh\|ryP	MnHVV2FPT0WU
ETK-1	NEHnd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jyeGlEPTB;MD6wNlc{PiEQvF2=	NYe2ZY14W0GQR1XS
TE-15	NUXOT45DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTBwMEK3N\|gh\|ryP	MVrTRW5ITVJ?
BE-13	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwMEK3OEDPxE1?	MoDmV2FPT0WU
KE-37	NHzBXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWxTWM2OD1yLkCyO\|QyKM7:TR?=	MkTYV2FPT0WU
NCI-H1355	NFLsemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L2SGlEPTB;MD6wNlc5OyEQvF2=	NHvpb2JUSU6JRWK=
TE-11	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;STWM2OD1yLkCyPFA6KM7:TR?=	MVfTRW5ITVJ?
BL-70	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMEK4OVch\|ryP	MmfuV2FPT0WU
ES6	M1j6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHhRodKSzVyPUCuNFI5QDFizszN	NYPpfWEyW0GQR1XS
GT3TKB	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTZWHRFUUN3ME2wMlAzQTV\|IN88US=>	NWXUcnVYW0GQR1XS
LB647-SCLC	NVO0ZolKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3ZcWprUUN3ME2wMlA{OTl3IN88US=>	MnS5V2FPT0WU
NB13	NVnoVo9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrwfoZKSzVyPUCuNFM{OTZizszN	NY\mN5A5W0GQR1XS
ST486	M{fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;pVZd3UUN3ME2wMlA{OzN5IN88US=>	NF[5fVRUSU6JRWK=
NCI-H82	M2nSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTxTWM2OD1yLkCzN\|Q{KM7:TR?=	NVG2PIdzW0GQR1XS
NTERA-S-cl-D1	NX:ycGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;ITWM2OD1yLkCzN\|k6KM7:TR?=	NEfFe41USU6JRWK=
ES4	NYfVd21sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIf3TW1KSzVyPUCuNFM1PjNizszN	MnzkV2FPT0WU
SK-NEP-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXWTFJRUUN3ME2wMlA{PDl7IN88US=>	MkG3V2FPT0WU
Becker	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTBwMEO1OVUh\|ryP	M1GzTnNCVkeHUh?=
A101D	NYfFXpV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HRVGlEPTB;MD6wN\|c1QCEQvF2=	NV3tRmN3W0GQR1XS
SK-UT-1	NYDmR5U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkH6TWM2OD1yLkCzO\|c1KM7:TR?=	NIfQSJFUSU6JRWK=
SW982	NF:yWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPzTWM2OD1yLkCzO\|kh\|ryP	NV\6dWhPW0GQR1XS
TE-10	NULaeW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVi4SZozUUN3ME2wMlA1ODR4IN88US=>	MUHTRW5ITVJ?
OVCAR-4	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLXTWM2OD1yLkC0NFU6KM7:TR?=	NV7KZ\|VTW0GQR1XS
KP-N-YS	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHJZYhKSzVyPUCuNFQxQDVizszN	NX7ZTIM{W0GQR1XS
BL-41	NFL3N5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3LNWZ4UUN3ME2wMlA1OTJ3IN88US=>	NFe0TGhUSU6JRWK=
MZ1-PC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTKU5NFUUN3ME2wMlA1OTJ5IN88US=>	M1nZfHNCVkeHUh?=
PF-382	NYfsXYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLENpJKSzVyPUCuNFQyQThizszN	NVnvUIRLW0GQR1XS
MOLT-13	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwMESyN\|gh\|ryP	NFTrUZVUSU6JRWK=
HCC1599	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PofWlEPTB;MD6wOFI2QCEQvF2=	NIjWXmlUSU6JRWK=
IST-MEL1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXyTWM2OD1yLkC0OFQzKM7:TR?=	NVruVndiW0GQR1XS
LU-139	M1HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnr5TWM2OD1yLkC0OFQzKM7:TR?=	NV3YcINJW0GQR1XS
MS-1	M{XEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH75W4RKSzVyPUCuNFQ4ODFizszN	Ml;MV2FPT0WU
MFH-ino	NWnjRlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljHTWM2OD1yLkC1NFA{KM7:TR?=	NEXkNmZUSU6JRWK=
IMR-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf4XY5MUUN3ME2wMlA2ODJzIN88US=>	MkPUV2FPT0WU
TE-5	NGfMTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwMEWwOlMh\|ryP	M2nBe3NCVkeHUh?=
DJM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj1OZFSUUN3ME2wMlA2OTR{IN88US=>	NE\4WmdUSU6JRWK=
NB17	NGrNdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwMEWyNFch\|ryP	NFv5TWlUSU6JRWK=
KARPAS-45	NFfrfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml72TWM2OD1yLkC1N\|U5KM7:TR?=	NF7pc\|RUSU6JRWK=
TGBC1TKB	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NES2W5lKSzVyPUCuNFU1ODVizszN	Mnf0V2FPT0WU
ML-2	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r6W2lEPTB;MD6wOVQyPCEQvF2=	MVjTRW5ITVJ?
no-10	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWf0[\|J3UUN3ME2wMlA2PDd2IN88US=>	M{DndHNCVkeHUh?=
CTV-1	NWC1UJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHmNXk5UUN3ME2wMlA2PTB{IN88US=>	Mlq2V2FPT0WU
SJSA-1	NWjHS\|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXPXlJKSzVyPUCuNFU2OiEQvF2=	Ml\nV2FPT0WU
HC-1	M4nqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{OwNmlEPTB;MD6wOVU6PyEQvF2=	M2TTc3NCVkeHUh?=
TE-12	NEfwdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHRW3Z6UUN3ME2wMlA2PjF\|IN88US=>	MnGxV2FPT0WU
KY821	M4rnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS2b41KSzVyPUCuNFU3OzJizszN	MnfXV2FPT0WU
TALL-1	M3fWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzBTWM2OD1yLkC1O\|A5KM7:TR?=	MVzTRW5ITVJ?
DEL	NWLSc21GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7a[YdjUUN3ME2wMlA2PzB7IN88US=>	MmHZV2FPT0WU
TE-6	NXPCWXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGG3fpFKSzVyPUCuNFU4OjJizszN	NXvVUIlXW0GQR1XS
SK-LMS-1	NFXYVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\pXWlEPTB;MD6wOVgxPSEQvF2=	NWW4W45[W0GQR1XS
EW-1	M{fFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfqXllCUUN3ME2wMlA2QDN5IN88US=>	Mo\KV2FPT0WU
8-MG-BA	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XDR2lEPTB;MD6wOVg2OSEQvF2=	MnTrV2FPT0WU
NALM-6	M1XUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfUTWM2OD1yLkC1PVc{KM7:TR?=	M{n0c3NCVkeHUh?=
LB771-HNC	NXjscFlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXk[YNsUUN3ME2wMlA2QTd7IN88US=>	NIm2UXZUSU6JRWK=
HT-144	Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nMWmlEPTB;MD6wOlE{KM7:TR?=	NFfj[\|BUSU6JRWK=
KM-H2	NIWwcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3H0[GlEPTB;MD6wOlIzOSEQvF2=	M4PRPHNCVkeHUh?=
SF268	NX;nc2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnv3TWM2OD1yLkC2Nlg3KM7:TR?=	NEDOTVdUSU6JRWK=
RS4-11	NGjRRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7vUYdqUUN3ME2wMlA3OzB2IN88US=>	NID6eGVUSU6JRWK=
MHH-PREB-1	NGLxdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwME[zNVkh\|ryP	NE[1[WdUSU6JRWK=
ATN-1	NWTS[5Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTh[2VFUUN3ME2wMlA3OzR3IN88US=>	MoThV2FPT0WU
BB30-HNC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwME[0N\|Yh\|ryP	M{XES3NCVkeHUh?=
CPC-N	M{nGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvrPWdKSzVyPUCuNFY2OjRizszN	MlnVV2FPT0WU
NB1	NILtR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorETWM2OD1yLkC2OlE{KM7:TR?=	M3nWRXNCVkeHUh?=
KS-1	NVTGPGk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\hRmRKSzVyPUCuNFY4PDhizszN	MYXTRW5ITVJ?
RXF393	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2foOGlEPTB;MD6wOlc3PCEQvF2=	MXvTRW5ITVJ?
IST-SL2	NX\zSmJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D5eGlEPTB;MD6wO\|AxPCEQvF2=	NG\iUoJUSU6JRWK=
GI-ME-N	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfjTWM2OD1yLkC3Nlg3KM7:TR?=	MUjTRW5ITVJ?
VA-ES-BJ	NX;mfHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPwbZdKSzVyPUCuNFc1PzVizszN	MoPFV2FPT0WU
NCI-H1581	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTBwMEe0O\|gh\|ryP	MV3TRW5ITVJ?
U-266	NFzPWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LOWGlEPTB;MD6wO\|Q6PyEQvF2=	M{L3NHNCVkeHUh?=
DMS-114	NHnzN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjJTWM2OD1yLkC3OVI5KM7:TR?=	M1HVWHNCVkeHUh?=
NCI-H187	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1va[mlEPTB;MD6wO\|czPiEQvF2=	MkLaV2FPT0WU
SW962	NIPDTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrrPYJqUUN3ME2wMlA4QDN7IN88US=>	NImxWnZUSU6JRWK=
MONO-MAC-6	M4n5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XqU2lEPTB;MD6wO\|k5PiEQvF2=	MXzTRW5ITVJ?
MOLT-16	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoX6TWM2OD1yLkC4NVIyKM7:TR?=	MX7TRW5ITVJ?
KNS-42	NYi0cYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvuTWM2OD1yLkC4NVYyKM7:TR?=	Mk[3V2FPT0WU
CMK	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTBwMEiyNlUh\|ryP	MXrTRW5ITVJ?
Ramos-2G6-4C10	NXflPZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\BeWlEPTB;MD6wPFIzPSEQvF2=	NUntfWx1W0GQR1XS
Daudi	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X3ZWlEPTB;MD6wPFI2PiEQvF2=	NFzDRYhUSU6JRWK=
NCI-H510A	NHfLO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMW49KSzVyPUCuNFg{OzZizszN	M2[3eXNCVkeHUh?=
LB831-BLC	NWDsTXViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPYclJKSzVyPUCuNFg2PjFizszN	NIDGOItUSU6JRWK=
HEL	NW\JcYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwMEi2Olgh\|ryP	M2jHOnNCVkeHUh?=
LU-134-A	M{TCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTBwMEi3NFgh\|ryP	M2nEe3NCVkeHUh?=
NCI-H1694	NYWyXIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHO2Vo5KSzVyPUCuNFg4PDRizszN	MnztV2FPT0WU
KGN	M3HoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMEi3OVkh\|ryP	MmH4V2FPT0WU
A253	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHJTWM2OD1yLkC4PFIzKM7:TR?=	MlzNV2FPT0WU
DG-75	NIfwUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XqVmlEPTB;MD6wPFkzOiEQvF2=	M3XIVXNCVkeHUh?=
MOLT-4	NH3Kbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HuSGlEPTB;MD6wPFk5OyEQvF2=	Mn;lV2FPT0WU
NCI-SNU-5	NYq2d25lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTBwMEmyOVgh\|ryP	NWLkfG52W0GQR1XS
ONS-76	Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLiTWM2OD1yLkC5Nlc3KM7:TR?=	MUDTRW5ITVJ?
NCI-H446	M2jrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMEm0OlIh\|ryP	NVz1NI1HW0GQR1XS
COR-L279	NHjuPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLKRWpDUUN3ME2wMlA6PTV4IN88US=>	MYHTRW5ITVJ?
Calu-6	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DtSmlEPTB;MD6wPVU6QCEQvF2=	M1Hn[XNCVkeHUh?=
BC-3	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\FdGlEPTB;MD6wPVY3OiEQvF2=	NWHlboE5W0GQR1XS
NCI-H2126	M3OyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TBWGlEPTB;MD6wPVc6OSEQvF2=	M{O5dHNCVkeHUh?=
NCI-H1882	NXrEb3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPMR\|JrUUN3ME2wMlA6QDB7IN88US=>	MoDlV2FPT0WU
BB65-RCC	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTjcI9KSzVyPUCuNVAzQTRizszN	MXTTRW5ITVJ?
DU-4475	M{DyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV6xeI0xUUN3ME2wMlExPDB5IN88US=>	NILSW2hUSU6JRWK=
NCI-H526	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwMUC0OEDPxE1?	NW\tNVlpW0GQR1XS
NEC8	NWDteVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L4eGlEPTB;MD6xNFUzPSEQvF2=	MXnTRW5ITVJ?
NCI-H1304	NXHVfXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjhTWM2OD1yLkGwOVk1KM7:TR?=	NXG2U2ZQW0GQR1XS
L-540	M{W5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTBwMUC3NFgh\|ryP	NHqxdohUSU6JRWK=
NCI-SNU-16	NV\zUXpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwMUC3OFIh\|ryP	NULtem9QW0GQR1XS
HD-MY-Z	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TLWWlEPTB;MD6xNFg2PiEQvF2=	MYLTRW5ITVJ?
K-562	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnCUphGUUN3ME2wMlExQDV6IN88US=>	NYfVNIY2W0GQR1XS
JAR	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL2fYVsUUN3ME2wMlExQTJ3IN88US=>	MkjqV2FPT0WU
MZ2-MEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWC1OHhEUUN3ME2wMlEyODVizszN	NYjMdHU2W0GQR1XS
L-363	NIq1SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TuWWlEPTB;MD6xNVA4QSEQvF2=	NWDtPIVlW0GQR1XS
BV-173	NF3ofIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPRVIlxUUN3ME2wMlEyOjR\|IN88US=>	NFu5SFBUSU6JRWK=
NCI-H524	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvDeGpKSzVyPUCuNVEzPzRizszN	NUfUc41GW0GQR1XS
EoL-1-cell	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\BTWM2OD1yLkGxOlczKM7:TR?=	M2jtNXNCVkeHUh?=
K052	M2LzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMUG3NVIh\|ryP	NWTCbHFGW0GQR1XS
TK10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfSWIVSUUN3ME2wMlEyPzJ6IN88US=>	M1\CT3NCVkeHUh?=
KU812	NE\WWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3jdHNKSzVyPUCuNVIxPDRizszN	NEHHXZhUSU6JRWK=
RPMI-8226	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVz3VlBSUUN3ME2wMlEzODV{IN88US=>	M3W3NHNCVkeHUh?=
MZ7-mel	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\LOGxKSzVyPUCuNVIzOzdizszN	NGLoPWRUSU6JRWK=
SK-PN-DW	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLCTWM2OD1yLkGyNlg4KM7:TR?=	M4HPenNCVkeHUh?=
SR	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMUK0OFEh\|ryP	NF20OYlUSU6JRWK=
RPMI-6666	M1TwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkm3TWM2OD1yLkGyO\|Q{KM7:TR?=	MonGV2FPT0WU
no-11	NWn3XphVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnO[3E4UUN3ME2wMlEzQDZ7IN88US=>	NFG5WlJUSU6JRWK=
EW-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzJ[JpKSzVyPUCuNVI5QTNizszN	MoTwV2FPT0WU
LAMA-84	Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrLbHhKSzVyPUCuNVMyQDdizszN	M1KxNHNCVkeHUh?=
HT	NWnuWHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTBwMUO1O\|Qh\|ryP	NX;aZWxMW0GQR1XS
KP-N-RT-BM-1	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwMUO2NVIh\|ryP	NVnRO\|FVW0GQR1XS
NCI-H747	NE\5W\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfYVGc4UUN3ME2wMlE{PyEQvF2=	MkiwV2FPT0WU
NCCIT	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwMUO5N\|kh\|ryP	NXPafHNmW0GQR1XS
MLMA	NEDsZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTBwMUSxOlch\|ryP	NHTiR2tUSU6JRWK=
LP-1	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHn5WXVKSzVyPUCuNVQzPCEQvF2=	NVy3d406W0GQR1XS
CAL-148	NHfWVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXSSWZKSzVyPUCuNVQ1QDNizszN	NHfFWnlUSU6JRWK=
GB-1	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTBwMUS1NlYh\|ryP	MUjTRW5ITVJ?
COR-L88	NH:2SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn4TWM2OD1yLkG0PFAzKM7:TR?=	M4TNb3NCVkeHUh?=
NKM-1	NVLQNldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f6e2lEPTB;MD6xOFkxPiEQvF2=	MX3TRW5ITVJ?
NB5	NYrDWlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDBVYtFUUN3ME2wMlE2PDZ{IN88US=>	NEPsOpBUSU6JRWK=
SH-4	NHm5OI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvNR\|RFUUN3ME2wMlE2PDZ4IN88US=>	M2fzUXNCVkeHUh?=
EM-2	M4fVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPFVFJKSzVyPUCuNVU1PjdizszN	MUTTRW5ITVJ?
TGBC24TKB	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Gwd2lEPTB;MD6xOVY2QSEQvF2=	MX3TRW5ITVJ?
SCLC-21H	MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfsV3RKSzVyPUCuNVU4ODJizszN	MkW4V2FPT0WU
COLO-684	M2HzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MornTWM2OD1yLkG1O\|IyKM7:TR?=	NVrNWolKW0GQR1XS
KINGS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W2[WlEPTB;MD6xOVkyKM7:TR?=	MlS1V2FPT0WU
LS-123	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXzemxKSzVyPUCuNVU6OTdizszN	M4f4[HNCVkeHUh?=
MC116	NWSx[Is1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi0d3hGUUN3ME2wMlE3OTV6IN88US=>	M37lUnNCVkeHUh?=
SU-DHL-1	NFvxVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTBwMU[yNFYh\|ryP	NX3kb\|Y5W0GQR1XS
NCI-H64	M{HTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrpNWhKSzVyPUCuNVY{PDdizszN	MkfqV2FPT0WU
HCE-T	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjuVm5KSzVyPUCuNVY2ODRizszN	MVXTRW5ITVJ?
LOXIMVI	M3LmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwMU[5OFkh\|ryP	M2K1OnNCVkeHUh?=
ARH-77	NVPXWm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTBwMUezO\|kh\|ryP	NXjDZ2RWW0GQR1XS
DOHH-2	M1rFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwMUe2O\|Ih\|ryP	NXLIV\|EzW0GQR1XS
COLO-320-HSR	M3THZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TZXGlEPTB;MD6xPFE2PCEQvF2=	M1PDO3NCVkeHUh?=
NB6	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLETWM2OD1yLkG4OVY3KM7:TR?=	NXzNT5p3W0GQR1XS
L-428	NGfLdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXUZ4NKSzVyPUCuNVg5OTNizszN	MX3TRW5ITVJ?
SNB75	M{XSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXyTWM2OD1yLkG4PFI1KM7:TR?=	MnP1V2FPT0WU
NCI-H2141	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPJWHgzUUN3ME2wMlE6ODFzIN88US=>	Mm\1V2FPT0WU
KARPAS-299	NIOwXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XZVGlEPTB;MD6xPVI1OSEQvF2=	NV[1NJZ2W0GQR1XS
LC4-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTBwMUm1NFIh\|ryP	NHf4SoVUSU6JRWK=
UACC-257	M4\odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf0UWpKSzVyPUCuNVk6PDdizszN	MlHIV2FPT0WU
EVSA-T	NIXEdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXBTWM2OD1yLkKwN\|EzKM7:TR?=	M3HhVXNCVkeHUh?=
JiyoyeP-2003	NFuw[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXRTWM2OD1yLkKwOFc4KM7:TR?=	NVrBTIFTW0GQR1XS
NCI-H720	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjOTWM2OD1yLkKwOVI2KM7:TR?=	NFuwT5lUSU6JRWK=
GAK	M1LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXVTWM2OD1yLkKxNVg6KM7:TR?=	M3HG[3NCVkeHUh?=
HH	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL4TVZqUUN3ME2wMlIyPDB3IN88US=>	NFLXeJFUSU6JRWK=
NCI-H1436	NIq0PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvI[2hKSzVyPUCuNlE1PjRizszN	M3TzO3NCVkeHUh?=
GR-ST	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETwZ49KSzVyPUCuNlE1QDhizszN	NETWWmVUSU6JRWK=
BC-1	NF3OUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULYeJpXUUN3ME2wMlIzPjF4IN88US=>	NXmwNox3W0GQR1XS
SIG-M5	MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPhTWM2OD1yLkKyO\|I4KM7:TR?=	MWHTRW5ITVJ?
NCI-H345	M2rIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\DO2FKSzVyPUCuNlM5ODVizszN	M{TlRXNCVkeHUh?=
OPM-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXIepNSUUN3ME2wMlI{QDh{IN88US=>	M3jTS3NCVkeHUh?=
LB1047-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PaeGlEPTB;MD6yOFQyKM7:TR?=	M1P0enNCVkeHUh?=
CTB-1	M3;MTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLPd\|lVUUN3ME2wMlI1PDl\|IN88US=>	M{L1cnNCVkeHUh?=
A3-KAW	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;SSWlEPTB;MD6yOVM1OSEQvF2=	M1fTOXNCVkeHUh?=
SF126	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnyNW5EUUN3ME2wMlI2Ozh\|IN88US=>	M1\hNHNCVkeHUh?=
KARPAS-422	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwMkW0N\|Uh\|ryP	NHjXUJhUSU6JRWK=
MEG-01	NIL3Z2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zoUGlEPTB;MD6yOVY4OyEQvF2=	NHjYZnlUSU6JRWK=
NCI-H209	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzhTYpKSzVyPUCuNlY{PzRizszN	MWLTRW5ITVJ?
SBC-1	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jDfGlEPTB;MD6yOlUh\|ryP	NHHFZYFUSU6JRWK=
K5	MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PuW2lEPTB;MD6yOlk5PCEQvF2=	M2rKcnNCVkeHUh?=
QIMR-WIL	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DwcmlEPTB;MD6yO\|E2PSEQvF2=	NEXTWW1USU6JRWK=
NMC-G1	NEjqdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTLWoxbUUN3ME2wMlI5OjF5IN88US=>	NHywVnlUSU6JRWK=
IST-MES1	NVize29WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjiTWM2OD1yLkK5NlM5KM7:TR?=	M4PYUnNCVkeHUh?=
SW684	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmX3TWM2OD1yLkOwNFQ4KM7:TR?=	NFrNZWRUSU6JRWK=
MV-4-11	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTBwM{C3PFgh\|ryP	NWSzSYRFW0GQR1XS
LAN-6	NH:wcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3DU2ZKSzVyPUCuN\|E2PzJizszN	M{nNSXNCVkeHUh?=
RH-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\DTWM2OD1yLkOxPFcyKM7:TR?=	MlzBV2FPT0WU
CP66-MEL	M1nvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X2OGlEPTB;MD6zNVg4QCEQvF2=	NXn1U25LW0GQR1XS
EC-GI-10	NXrIR2pRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jERmlEPTB;MD6zNlk5PyEQvF2=	NFWwXIZUSU6JRWK=
GDM-1	NV22VldvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwM{OwOVkh\|ryP	NXHEWlk5W0GQR1XS
IST-SL1	M1Wzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLtd2dKSzVyPUCuN\|Q6OTRizszN	NWe4bYpiW0GQR1XS
KMOE-2	M4fINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jVS2lEPTB;MD6zOVE4PSEQvF2=	NHriR\|dUSU6JRWK=
OS-RC-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwM{W1OFQh\|ryP	M4LqcnNCVkeHUh?=
HDLM-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTPSlVKSzVyPUCuN\|c5OTRizszN	MoX0V2FPT0WU
DSH1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmi5TWM2OD1yLkO4OlMyKM7:TR?=	MXfTRW5ITVJ?
LS-1034	NGrKUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jU[mlEPTB;MD6zPFk2PCEQvF2=	NFnsS5ZUSU6JRWK=
LB373-MEL-D	NGXjc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwM{mxPVch\|ryP	MkL3V2FPT0WU
GOTO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G5bmlEPTB;MD60NlEyQCEQvF2=	MVPTRW5ITVJ?
MRK-nu-1	NHf3cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPJbJFKSzVyPUCuOFIzODVizszN	MnLIV2FPT0WU
SK-MM-2	M2jzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwNEO0OFIh\|ryP	NYroTW0{W0GQR1XS
BOKU	NFPWfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;sXVhKSzVyPUCuOFM4QTJizszN	NV\1V5ZlW0GQR1XS
NOMO-1	M3rqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPZU\|k6UUN3ME2wMlQ{QDZizszN	MVTTRW5ITVJ?
J-RT3-T3-5	NF\Sd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwNES4O\|gh\|ryP	MUDTRW5ITVJ?
COLO-668	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\wcFBKSzVyPUCuOFU3PjhizszN	MXHTRW5ITVJ?
SF539	M33yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3tTWM2OD1yLkS4Olg1KM7:TR?=	MVjTRW5ITVJ?
LB2518-MEL	NXu1d444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;5bZpKSzVyPUCuOFk4ODNizszN	NX\zWY1VW0GQR1XS
TE-441-T	M2LoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrMTWM2OD1yLkWwNVIh\|ryP	M3fhfnNCVkeHUh?=
MDA-MB-134-VI	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3oVpBKSzVyPUCuOVA6OjFizszN	M3PM[XNCVkeHUh?=
SCC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjS[GZKSzVyPUCuOVE5PzNizszN	NXHIUow1W0GQR1XS
KLE	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTBwNUKxO\|Eh\|ryP	MVPTRW5ITVJ?
LB2241-RCC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu5eohKSzVyPUCuOVI2OjVizszN	M33CRnNCVkeHUh?=
NCI-H1417	NWfNN4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkT1TWM2OD1yLkWzOFM2KM7:TR?=	M37ZOHNCVkeHUh?=
NCI-H2081	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWryUIFbUUN3ME2wMlU5PjFzIN88US=>	NXnRXGk5W0GQR1XS
NCI-H1522	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTBwNUmzPFMh\|ryP	MX3TRW5ITVJ?
NCI-H889	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TlOWlEPTB;MD61PVg1PCEQvF2=	M2fCW3NCVkeHUh?=
CGTH-W-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PacWlEPTB;MD62NFc2PSEQvF2=	MnvaV2FPT0WU
EB-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwNkGxOVMh\|ryP	MXPTRW5ITVJ?
D-336MG	NHTBbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTBwNkG3PVEh\|ryP	MX\TRW5ITVJ?
LC-1F	NUC0fZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPOcmNKSzVyPUCuOlI2QTJizszN	NWPGT2xEW0GQR1XS
MHH-NB-11	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTBwNkO4NFEh\|ryP	NYXqfJYxW0GQR1XS
SK-N-FI	NWrESIhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HMPWlEPTB;MD62N\|kyKM7:TR?=	M3f0c3NCVkeHUh?=
NCI-H69	M3nZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwNkS4O\|kh\|ryP	NWTWfI1XW0GQR1XS
SCH	NXHTbXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjFNVVKSzVyPUCuOlYxOjNizszN	MUHTRW5ITVJ?
LS-513	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETkXZNKSzVyPUCuOlczPTlizszN	MWPTRW5ITVJ?
CP67-MEL	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwNke1PVYh\|ryP	MX7TRW5ITVJ?
GCIY	NFHXSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTBwN{CzOlMh\|ryP	M3vwTnNCVkeHUh?=
SHP-77	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXES\|JKSzVyPUCuO\|A4OzRizszN	NILMSJFUSU6JRWK=
EHEB	NGDnVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwN{G4OVQh\|ryP	NIXIV3hUSU6JRWK=
D-247MG	NW\IfYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\JR2lEPTB;MD63N\|I{OiEQvF2=	M{LvfnNCVkeHUh?=
Raji	M1XNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwN{S5PFkh\|ryP	MnLYV2FPT0WU
MPP-89	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwN{W5O\|gh\|ryP	NVnyUIpVW0GQR1XS
EKVX	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7F[opKSzVyPUCuO\|kxPzNizszN	M1m2NnNCVkeHUh?=
HCC2218	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjFTWM2OD1yLke5NVMyKM7:TR?=	NUXmfY5vW0GQR1XS
KNS-81-FD	NXPnVJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfuVnlKSzVyPUCuPFExOTFizszN	MWnTRW5ITVJ?
HCC2157	NE\rUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\HSHAxUUN3ME2wMlg1QTVzIN88US=>	MYLTRW5ITVJ?
BT-474	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLCTWM2OD1yLki4PFU1KM7:TR?=	MWXTRW5ITVJ?
NCI-H748	M4TzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwOUGyJO69VQ>?	NYW2NJo6W0GQR1XS
EW-24	NFnteYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWflfWhFUUN3ME2wMlkzODB{IN88US=>	NV7PXmJkW0GQR1XS
D-263MG	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPsTWM2OD1yLkm0OVEzKM7:TR?=	M{j1UXNCVkeHUh?=
OMC-1	NVjTWpFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHo[4lFUUN3ME2wMlk3Ozd\|IN88US=>	Mlr4V2FPT0WU
NCI-H2196	NF61foVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLaTWM2OD1yLkm3O\|c4KM7:TR?=	M{HGdXNCVkeHUh?=
HAL-01	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwOUm4O\|Ih\|ryP	MWrTRW5ITVJ?
NCI-H2107	NHTqU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PseWlEPTB;MT6wNVg2PCEQvF2=	NELxVnpUSU6JRWK=
LB996-RCC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonVTWM2OD1zLkC4NFUyKM7:TR?=	MWHTRW5ITVJ?
NCI-H1395	M3TQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLu[XJEUUN3ME2xMlExPjdizszN	MVfTRW5ITVJ?
CHP-126	NFvt[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;xTWM2OD1zLkG2NVk6KM7:TR?=	MYTTRW5ITVJ?
NB69	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwMk[xOFgh\|ryP	NWjObmE{W0GQR1XS
CAS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwM{SyN\|Eh\|ryP	MkD4V2FPT0WU
JVM-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\qTWM2OD1zLkS3PFU2KM7:TR?=	MkTFV2FPT0WU
DMS-153	NGfq[\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTFwNUe2O\|Qh\|ryP	NV3pRWhmW0GQR1XS
SK-MEL-2	M1uxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn2OmlKSzVyPUGuO\|E4QDlizszN	NYLNNHNHW0GQR1XS
NCI-H1155	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTFwN{O2O\|Yh\|ryP	M4i1b3NCVkeHUh?=
NCI-H1092	NFu5WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTOTWM2OD1zLke2NVgzKM7:TR?=	M1T1S3NCVkeHUh?=
LU-165	NFTpUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;uTWM2OD1zLki2OFc3KM7:TR?=	MnrhV2FPT0WU
HL-60	NIO0TZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTVZmdKSzVyPUGuPVk6ODhizszN	Mn\lV2FPT0WU
REH	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7UR4xKSzVyPUKuNFA2QDJizszN	NXvTeFc3W0GQR1XS
JVM-2	M1X5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;sW5hOUUN3ME2yMlA3OTN3IN88US=>	NHu4WoFUSU6JRWK=
MN-60	NY\pUXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XoWmlEPTB;Mj6xO\|MxQCEQvF2=	NGTrWZVUSU6JRWK=
SCC-15	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXaTWM2OD1{LkKwNlch\|ryP	NYjSTFlUW0GQR1XS
SNU-C1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTJwMkGzOFMh\|ryP	MY\TRW5ITVJ?
SK-MEL-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnlTWM2OD1{LkOyNFQ4KM7:TR?=	NFG3TGVUSU6JRWK=
TGW	M{PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlWzTWM2OD1{LkO1NFI4KM7:TR?=	NGn2No9USU6JRWK=
CA46	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJwN{W5Olch\|ryP	NUL6U3ZbW0GQR1XS
NCI-H23	M3H1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPvTWM2OD1{LkiwO\|kyKM7:TR?=	NHHVWWtUSU6JRWK=
MMAC-SF	M2XWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjQNFJ6UUN3ME2yMlg3PjJ6IN88US=>	MnPZV2FPT0WU
NCI-H2171	NWPTeWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfLcVhKSzVyPUOuNFM1PDhizszN	NHrvTnFUSU6JRWK=
A704	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPBdY5KUUN3ME2zMlE1OTl2IN88US=>	NXuxe2FXW0GQR1XS
DB	NFvnTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrDTZdiUUN3ME2zMlI2PTd4IN88US=>	MormV2FPT0WU
NCI-H719	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPPTWM2OD1\|LkOwN\|g1KM7:TR?=	MkfnV2FPT0WU
MC-CAR	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\HXoU1UUN3ME2zMlU1QDF5IN88US=>	NH;GZoJUSU6JRWK=
SIMA	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTNwNUi0NVYh\|ryP	NF34NWtUSU6JRWK=
SW872	M1Gxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;VfmlEPTB;Mz63PFExOSEQvF2=	MnfnV2FPT0WU
HCC1187	NGPHcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTNwN{izNVUh\|ryP	NFTzfZBUSU6JRWK=
EW-13	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLnVYd1UUN3ME2zMlg{PDF5IN88US=>	M3PKbnNCVkeHUh?=
NCI-SNU-1	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C1bWlEPTB;ND6yNVk6QSEQvF2=	NX7SRnM{W0GQR1XS
NCI-H226	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HXTmlEPTB;ND6zN\|YxPiEQvF2=	MUXTRW5ITVJ?
RPMI-8866	NX32e4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M164d2lEPTB;ND6zOlAzQSEQvF2=	M4jaenNCVkeHUh?=
OCI-AML2	M3GwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3mTWM2OD12LkW1NlMh\|ryP	M3jiSHNCVkeHUh?=
LU-65	NGfoWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3joXmlEPTB;ND65N\|A{OyEQvF2=	MlzxV2FPT0WU
SK-N-DZ	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLBTWM2OD13Lk[zOFY2KM7:TR?=	NHnVO3ZUSU6JRWK=
NB14	NVfkOoljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnETWM2OD13Lkm3NVM2KM7:TR?=	MXLTRW5ITVJ?
COLO-829	NITi[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jUZ2lEPTB;Nj6zN\|M2QSEQvF2=	NFvmO\|BUSU6JRWK=
MHH-CALL-2	NG\6[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTlOZJ[UUN3ME22MlUyPTB6IN88US=>	MlX6V2FPT0WU
NCI-H1770	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTZwNk[5NFQh\|ryP	NFflXIFUSU6JRWK=
ECC4	NWKzPHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjRU3JKSzVyPU[uPFIyPzlizszN	NXToWGVtW0GQR1XS
A498	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3L5R2lEPTB;Nj64O\|E6OiEQvF2=	MYPTRW5ITVJ?
DMS-79	NX\QVpJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXy0OGluUUN3ME23MlA1PTF{IN88US=>	MUDTRW5ITVJ?
P30-OHK	NFO2[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTdwMkG5NFYh\|ryP	NHraZ3pUSU6JRWK=
D-502MG	M3TLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnnTlNzUUN3ME23Mlk5OzZizszN	NWDRdphHW0GQR1XS
RCC10RGB	M1zVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRThwME[yPEDPxE1?	NWX3Z2hUW0GQR1XS
U-698-M	NH61bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRThwMkmyNlYh\|ryP	MX3TRW5ITVJ?
BB49-HNC	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LwT2lEPTB;OT60NlI3PSEQvF2=	NEjtc5dUSU6JRWK=
ES1	NYPwV3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHDTWM2OD17Lk[4PVU3KM7:TR?=	MU\TRW5ITVJ?
MFM-223	NVfle\|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ToVWlEPTB;MUCuPVkzPyEQvF2=	NFT3R5ZUSU6JRWK=
C2BBe1	M1f3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXMfpFKSzVyPUGxMlM2OjNizszN	MYjTRW5ITVJ?
EB2	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTF{Lk[4PFEh\|ryP	M{i1dnNCVkeHUh?=
C8166	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTtS5dKSzVyPUGzMlg{ODNizszN	MXTTRW5ITVJ?
ES3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TuUWlEPTB;MUOuPVk4PyEQvF2=	MWLTRW5ITVJ?
NCI-H1650	M1zFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7VUJozUUN3ME2xOk4{PzZ3IN88US=>	NUSzOmROW0GQR1XS
Mo-T	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLQTWM2OD1zNz60NFI6KM7:TR?=	MYHTRW5ITVJ?
NB7	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF5Lke0Olch\|ryP	M3HW[HNCVkeHUh?=
ES7	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTF7LkW1NFch\|ryP	NVrY[JBvW0GQR1XS
ES5	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LRTmlEPTB;MkGuO\|Y4OSEQvF2=	M2\menNCVkeHUh?=
MSTO-211H	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJzLki4OVgh\|ryP	MWDTRW5ITVJ?
U-87-MG	NH\ORZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ3LkG5OlYh\|ryP	NH\TdohUSU6JRWK=
THP-1	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJ7LkeyNFEh\|ryP	NX7NVJhiW0GQR1XS
NB10	NYDZO5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzuZ\|BKSzVyPUOwMlI3QTRizszN	M120fXNCVkeHUh?=
NH-12	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTN\|LkKwNVch\|ryP	NXvlVmN4W0GQR1XS
COLO-824	MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PEdmlEPTB;M{SuNVAxPiEQvF2=	M{LNc3NCVkeHUh?=
SKM-1	M4DofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjWXZdKSzVyPUO3Mlg1OjJizszN	M1mwOHNCVkeHUh?=
NCI-H1838	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\tZ3JWUUN3ME2zPE4{Pzl5IN88US=>	Mn;KV2FPT0WU
RL	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTN7LkK0O\|ch\|ryP	MoTuV2FPT0WU
COLO-800	M{f4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTRyLkC3O\|Mh\|ryP	MXjTRW5ITVJ?
KG-1	NVLCSot{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHWWWxjUUN3ME20NE45QTV3IN88US=>	NVTUNnhWW0GQR1XS
TUR	NFLXWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFezXnFKSzVyPUSxMlY{QTlizszN	NVP1OG5[W0GQR1XS
LNCaP-Clone-FGC	M{HLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTRzLkmwNVch\|ryP	M37DbXNCVkeHUh?=
NCI-H322M	NWPNN\|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LFTGlEPTB;NEKuOVk5PCEQvF2=	MUHTRW5ITVJ?
LNCaP	NWewUHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfTW4lKSzVyPUmxMlMhdk1?	Mk\vNlU2ODVzN{S=
C4-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkn3TWM2OD16IH7N	MoLzNlU2ODVzN{S=
JURKAT	M3:3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH3vfnUzPCCq		MUjJR\|UxRTRzNj62OkBvVQ>?	M4\kdFI1PTF7OUm1
MOLT-4	NFvnWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{\pWVI1KGh?		Mke3TWM2OD1{OEWzMlUhdk1?	MlLLNlQ2OTl7OUW=
REH	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnQbYszPCCq		NEjJV5FKSzVyPUK4O{43QCCwTR?=	NFH1bnczPDVzOUm5OS=>
NALM-6	NU\NWJQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXSyOEBp		NHfvSolKSzVyPUO0N\|MxKG6P	NWXrem5[OjR3MUm5PVU>
RS 4;11	NWnDUmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFfQWWszPCCq		Ml3nTWM2OD13MUmuNFUhdk1?	NX7scncxOjR3MUm5PVU>
697	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH22RmczPCCq		MXrJR\|UxRTJzMEeuNUBvVQ>?	MYqyOFUyQTl7NR?=
SIL-ALL	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYK5NY11OjRiaB?=		M1nQUGlEPTB;MUm5Mlc4KG6P	MkfLNlQ2OTl7OUW=
CEM	M4TYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NISzboQzPCCq		MXHJR\|UxRTV{LkG4JI5O	NH7rN2czPDVzOUm5OS=>
P12	NGL1U5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmXaNlQhcA>?		NUWwfIxYUUN3ME2zPU4zPyCwTR?=	M{HsNFI1PTF7OUm1
NALM-16	M{DUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLkPXY3OjRiaB?=		NFvIWIRKSzVyPUm2MlI5KG6P	MlHrNlQ2OTl7OUW=
JURKAT	M{DYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXBOFghcA>?		M{DsS2lEPTB;MUSuPFQhdk1?	NGnvZXQzPDVzOUm5OS=>
MOLT-4	NIjq[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MljzOFghcA>?		MofSTWM2OD1{Nj62JI5O	MVyyOFUyQTl7NR?=
REH	NXHvOoR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nGNVQ5KGh?		M4PhSmlEPTB;NESuO\|Ehdk1?	NHvwVYQzPDVzOUm5OS=>
NALM-6	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDCZ4c1QCCq		NGPhVnlKSzVyPUKzMlI3KG6P	MWGyOFUyQTl7NR?=
RS 4;11	M3zLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVm0PEBp		MYjJR\|UxRTF4ND6yPEBvVQ>?	Mm\4NlQ2OTl7OUW=
697	NHjmTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWO0PEBp		MnjPTWM2OD1\|MEWuN{BvVQ>?	MljaNlQ2OTl7OUW=
SIL-ALL	M1HWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIHvSo01QCCq		M4HtTWlEPTB;N{SuOlIhdk1?	NYTaTVdPOjR3MUm5PVU>
CEM	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWi4fHB[PDhiaB?=		M4TnN2lEPTB;MkSuOVUhdk1?	MV[yOFUyQTl7NR?=
P12	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVe0PEBp		MWfJR\|UxRTF6LkS2JI5O	MlLQNlQ2OTl7OUW=
NALM-16	M4jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUTuR2p3PDhiaB?=		MYXJR\|UxRTZ\|LkK0JI5O	MnXXNlQ2OTl7OUW=
JURKAT	NWqwd2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnXjO\|IhcA>?		NFT3[XFKSzVyPUOuOlUhdk1?	NF33OGszPDVzOUm5OS=>
MOLT-4	M1HiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVS3NkBp		MlvkTWM2OD15LkO5JI5O	NUPqWZlIOjR3MUm5PVU>
REH	NITqWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVW3NkBp		MkDPTWM2OD1zNj6wNUBvVQ>?	M4LBclI1PTF7OUm1
NALM-6	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUDvO\|N[PzJiaB?=		M{PCNWlEPTB;MT63PEBvVQ>?	NXnGbm17OjR3MUm5PVU>
RS 4;11	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXri[2huPzJiaB?=		MoDmTWM2OD12LkO4JI5O	MYiyOFUyQTl7NR?=
697	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DJOVczKGh?		NV\u[oZYUUN3ME23OE4zQCCwTR?=	MoTVNlQ2OTl7OUW=
SIL-ALL	NULQdHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV63NkBp		Mo[0TWM2OD15LkKgcm0>	MYWyOFUyQTl7NR?=
CEM	NVfBOZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nwTFczKGh?		MXzJR\|UxRTVwNEKgcm0>	NUT0S4tyOjR3MUm5PVU>
P12	M1vPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYO4clg4PzJiaB?=		MmDtTWM2OD14LkO3JI5O	MUWyOFUyQTl7NR?=
NALM-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2m2eFczKGh?		MnK0TWM2OD15Nz63N{BvVQ>?	MUiyOFUyQTl7NR?=
Y79	MXHBdI9xfG:\|aYOgRZN{[Xl?	NIHPc2EyNTVyIH7N	NHWyUHUyOi9{NDDo	NIDTTmJFVVOR	M4WzSIlv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=>	NYHSVpBROjR\|Nk[2OlU>
WER-Rb-1	NIX3OIpCeG:ydH;zbZMhSXO\|YYm=	NFjDUXcyNTVyIH7N	NIPvTFYyOi9{NDDo	M4DBPGROW09?	MVjpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	MUWyOFM3PjZ4NR?=
G7	NHjsS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwMzDuUS=>	M135dlI1OjB2N{Oz
G166	M3fafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;tTWM2OD15LkCgcm0>	MnnvNlQzODR5M{O=
CB660	NEfCbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\1VI9KSzVyPU[uOEBvVQ>?	NFrOUJkzPDJyNEezNy=>
CB1117	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn1Wo9OUUN3ME2xOU43KG6P	MUOyOFIxPDd\|Mx?=
KB-3-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrpO3BKSzVyPUGuOFghyrFiMD61N{BvVQ>?	NFnI[5QzOzl4MkS0OS=>
KB-8-5-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrwfXFKSzVyPUWuNFEhyrFiMj6wNUBvVQ>?	MXWyN\|k3OjR2NR?=
KB-C-1	M33hdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHW2[lRKSzVyPUG2Mlc3KMLzIESuOVEhdk1?	NYPmdVc5OjN7NkK0OFU>
KB-V-1	NGjaWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1KyRWlEPTB;MkixMlI1KMLzIEOxMlU4KG6P	M4Dpc\|I{QTZ{NES1
OVCAR-8	NFnMcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;rTWM2OD15LkG5JOKyKDNwNkCgcm0>	Ml60NlM6PjJ2NEW=
NCI-ADR-RES	NFvPfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	NEfZSlIzOzl4MkS0OS=>
MCF7	NUXQbJg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mom2TWM2OD13LkGxJOKyKDFwNEegcm0>	MUGyN\|k3OjR2NR?=
MCF7-FLV1000	M{\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoOzTWM2OD1\|OUOuNVghyrFiN{SuPFMhdk1?	NEHiPGkzOzl4MkS0OS=>
S1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LkOWlEPTB;MkSuN\|AhyrFiND63OUBvVQ>?	M{exNlI{QTZ{NES1
S1-M1-80	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPtPGhKSzVyPUK2NU4xPiEEsTC0PE4zPSCwTR?=	MVSyN\|k3OjR2NR?=
CORL-23/P	NIG5cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXSWYRKSzVyPUSuN\|ghyrFiMT6yOUBvVQ>?	NUfVfZRYOjN7NkK0OFU>
CORL-23/R	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPrTWM2OD13LkG2JOKyKDFwOEOgcm0>	MmK3NlM6PjJ2NEW=
NIH3T3	NYDLb4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUX1cXBIUUN3ME20NE43OCEEsTC0Mlk4KG6P	MVWyN\|k3OjR2NR?=
NIH3T3-G185	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K1S2lEPTB;MkSxN{41OCEEsTC0NlMvPjZibl2=	M3:1dVI{QTZ{NES1
pcDNA-HEK293	NEjNTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTwPXFzUUN3ME2yMlc2KMLzIECuOlchdk1?	NWnSWJYzOjN7NkK0OFU>
MDR19-HEK293	NGLsSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjJelUzUUN3ME24OU42OCEEsTCxN{43PyCwTR?=	NIj4elkzOzl4MkS0OS=>
R482-HEK293	M133dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPOTWM2OD1{NT65O{DDuSB2Lkm1JI5O	NHT6T4ozOzl4MkS0OS=>
MRP1-HEK293	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTWTVVKSzVyPUKuPVkhyrFiMT60PUBvVQ>?	NEjWXIUzOzl4MkS0OS=>
SF188	M{HTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TMcVExNTFyMDDuUS=>	M3exSlI1NTl4IHi=	MV;EUXNQ	MnvTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj2g[IVx\WSnboSgcYFvdmW{	MUmyN\|g5PzZ2NR?=
T98G	NXyxd2RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfj[JYyOC1zMECgcm0>	NH\2eW4zPC17NjDo	NXy1foFITE2VTx?=	MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	NV3OT5g2OjN6OEe2OFU>
DU145	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEDFSYpFVVOR	MWXJR\|Ux6oj:NkCgcm0>	NGXFUogzOzh6NESyPC=>
LNCaP	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mnj6SG1UVw>?	NWHaWWlpUUN3MPMIwFc2KG6P	Mn2zNlM5QDR2Mki=
PC3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fte2ROW09?	MXrJR\|Ux6oj:MUe1JI5O	M{LxUFI{QDh2NEK4
RT4	NVTnOVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTJ5LkKxJI5O	MnjWNlM4QTJ4M{m=
5637	NYf0VIZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTR3LkS3JI5O	NGLHOG0zOzd7Mk[zPS=>
T24	NHfH[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF2xbWtKSzVyPUe5MlEzKG6P	NYHONpNZOjN5OUK2N\|k>
MCF7	MWDGeY5kfGmxbjDBd5NigQ>?	MV[xNFAhdk1?	MmG1NUBp	MWTEUXNQ	NE\Vcldz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3dCpGdz\WJzLNMgV4dsOS{EoGDzNkzDqFOncoDpcoE{NCCjbnVCpHdqe3B{	M4HwPVI{PzdyMkS0
KB-V1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPYTWM2OD1\|LkmyJO69VQ>?	M{PpPVI{PTl\|MUm2
Hec50co	M2TPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;XZWg{UUN3ME21JI5O	NH;YOVEzOzF2Nk[4Oy=>
MDA-MB-468	MVPBdI9xfG:\|aYOgRZN{[Xl?	NY\IT\|lROS93L{GwJI5O	NVPzPYt[OjRxNEivO\|IhcA>?	NFXYSnVFVVOR	M{jFUIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGLCdWUzOzF2NEK5OC=>
MCF10A	NF3OWotCeG:ydH;zbZMhSXO\|YYm=	MXOxM\|UwOTBibl2=	MlfxNlQwPDhxN{KgbC=>	M{TV[GROW09?	NFK1V\|NqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmDONlMyPDR{OUS=
Huh-7	Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Lx[lEwOTBxMUCwM\|ExODBibl2=	NHrINJg1QCCq		Moq5[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5	MUOyNlc1PTV6Nx?=
Daoy	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrH[3AyNjh5NT2yOFAhdk1?	M2\ITFczKGh?	NUDKNJVCTE2VTx?=	M37Ke2lEPTB;NTDuUS=>	M1PIcVIzOzlyMke5
ONS-76	M{XTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WxV\|EvQDd3LUK0NEBvVQ>?	NXrD[lNuPzJiaB?=	MkP3SG1UVw>?	NHTvVYZKSzVyPUeuOUBvVQ>?	M1vPS\|IzOzlyMke5
SUM 149	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrFNE0yODBibl2=	NWHVfZI5PzJiaB?=		MmDhbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	MUmyNlMxQTl\|OR?=
MDA-MB-231	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfBPWdUOC1zMECgcm0>	M3XTfFczKGh?		NXfmZnFwcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MVWyNlMxQTl\|OR?=
HR5	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonWNE0yODBibl2=	NVr3[5F5PzJiaB?=		MV\pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NHH5VWczOjNyOUmzPS=>
BT-474-M1	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmwMVExOCCwTR?=	MmmzO\|IhcA>?		M1vTb4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NEfBZpYzOjNyOUmzPS=>
AU565	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnVV5pjOC1zMECgcm0>	NFjjN\|U4OiCq		NI\DenNqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MWGyNlMxQTl\|OR?=
T47D	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\DVVAuOTByIH7N	NHq4O444OiCq		M{\QWolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NYTNWGtLOjJ\|MEm5N\|k>
MCF7	NX;EUnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4OwPVAuOTByIH7N	MljGO\|IhcA>?		NX\jN\|dDcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MonYNlI{ODl7M{m=
HCT116p53(+/+)	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fPeVExNTFyMECgcm0>	MkDVNlQwPDhiaB?=		MnzRbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0>	MYeyNlI3OjF5MR?=
HCT116p53(-/-)	NX;lUJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjoZmIyOC1zMECwJI5O	MXmyOE81QCCq		M4rnSYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6KGG2IEK1JI5O	NHPXfGQzOjJ4MkG3NS=>
HeLa	NHj3RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHmTZdxOTBvMUCwJI5O	M3fqcVQ5KGh?	MXHEUXNQ	NELFdIFKSzVyPUWyMlkhdk1?	NHrkVFUzOjB6MEKzOS=>
HeLa	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\3U3QyOC1zMECgcm0>	M2\2blczKGh?	M1rS[WROW09?	NUG5OFE6UUN3ME21NE42KG6P	M{m4dlIzODhyMkO1
GBC	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTzO\|IhcA>?		MUnJR\|UxRTF2Lke4JI5O	M3e1[\|IyQTZ3N{O5
GB-CL-1	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2f5XFczKGh?		Mk\ZTWM2OD13LkKyJI5O	Mni4NlE6PjV5M{m=
Mz-ChA-2	NUCz[WhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mke2O\|IhcA>?		NXWyNpZjUUN3ME2zMlMyKG6P	MX6yNVk3PTd\|OR?=
TGBC1-TKB	M4OwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\vOGsyPDRiaB?=		M{nFXGlEPTB;Nj63NkBvVQ>?	NV3HW3Z2OjF7NkW3N\|k>
Wittier	M1f1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWK3NkBp		MkHoTWM2OD1\|LkK2JI5O	NHzmXY4zOTl4NUezPS=>
H-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1LlU\|czKGh?		MYTJR\|UxRTlwNUSgcm0>	NVrQZ3I3OjF7NkW3N\|k>
HuH-28	NH;DTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmLwO\|IhcA>?		NIfaVGJKSzVyPUGxMlE6KG6P	MmHxNlE6PjV5M{m=
NEC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MU[3NkBp		NXjxZ3FvUUN3ME25Mlk5KG6P	NVPV[IRNOjF7NkW3N\|k>
REB	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkP3O\|IhcA>?		NXe1fm1tUUN3ME2xN{42OSCwTR?=	MXuyNVk3PTd\|OR?=
CC-LP-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfnS416PzJiaB?=		NV75cGN7UUN3ME21Mlg1KG6P	NUjpW5liOjF7NkW3N\|k>
CC-SW-1	M2\1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MorqO\|IhcA>?		M{TFfGlEPTB;OT61OUBvVQ>?	M1nIb\|IyQTZ3N{O5
EGI-1	M3rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWC3NkBp		NXP0UoxJUUN3ME2xNE44OiCwTR?=	NWrtfGtJOjF7NkW3N\|k>
Sk-ChA-1	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnXLO\|IhcA>?		MkTzTWM2OD1zNz6yJI5O	M1fs[\|IyQTZ3N{O5
TFK-1	M3\VWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXi3NkBp		NGH1T2VKSzVyPUGzMlQ2KG6P	M4\3VVIyQTZ3N{O5
786-O	NV\YU5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPEPZJjPS16MDDuUS=>	M{jhdFk3KGh?	NHT2SI9JS2x?	NXzoN5hLe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	NHXnZ2czOTZ2MkO3OC=>
A498	M2XETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIG5b\|g2NThyIH7N	Mn\FPVYhcA>?	MULIR4w>	NU\ZZolXe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MVKyNVY1OjN5NB?=
ACHN	NITEfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j3flUuQDBibl2=	MkTEPVYhcA>?	MoXXTGNt	MkLld5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6P	NEm2[HAzOTZ2MkO3OC=>
Caki-1	NVu0NHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYi1MVgxKG6P	MVm5OkBp	M1y5b2hEdA>?	NF[2Z5h{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	NGn0S3gzOTZ2MkO3OC=>
SN12C	NVnKe4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH[2XY42NThyIH7N	M1rGR\|k3KGh?	NGjRSZVJS2x?	MV7zeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	Mmf1NlE3PDJ\|N{S=
HMC-1.1	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2W1NVEuOTByMDDuUS=>	NH72bG04OiCq		MWnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MkjxNlEzPDJzOEm=
HMC-1.2	Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHSb3MyNTFyMECgcm0>	NYXTdXFTPzJiaB?=		NWHxeFJ2cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	NX3VXJpDOjF{NEKxPFk>
C2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUGxMVExODBibl2=	NI[yd2Q4OiCq		MnvHbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	MmTmNlEzPDJzOEm=
CHP-212	NFLvUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLwXYR[OS1zMkWgcm0>	MWSyOE0yOjBiaB?=		NUnZPYdqcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MU[yNVE3QTJ2Mh?=
IMR-32	M4\zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\LUVUyNTF{NTDuUS=>	NH[2dpkzPC1zMkCgbC=>		MoLmbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NGfh[nYzOTF4OUK0Ni=>
Kelly	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfsbIwyNTF{NTDuUS=>	M3O1e\|I1NTF{MDDo		M1jKW4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MUOyNVE3QTJ2Mh?=
SH-EP	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1OzSlEuOTJ3IH7N	NV3VXHhJOjRvMUKwJIg>		NHrlOI9qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MWSyNVE3QTJ2Mh?=
SH-SY5Y	NVLmXWpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxMVEzPSCwTR?=	M3\P[FI1NTF{MDDo		MnrybY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NHr1U2czOTF4OUK0Ni=>
SK-N-AS	NYS4SZJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKxMVEzPSCwTR?=	M1XMR\|I1NTF{MDDo		M2n2NYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MXqyNVE3QTJ2Mh?=
SK-N-BE	NHPTcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVGxMVEzPSCwTR?=	MXeyOE0yOjBiaB?=		MY\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M1\RfVIyOTZ7MkSy
KG1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\0NU8yOC9zMECgcm0>	MWq3NkBp	MVzEUXNQ	M1jwTolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NEfmepcyQTR3OEO1PC=>
U937	NFL0emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjxeYtNOS9zMD:xNFAhdk1?	M1TJblczKGh?	M3HqeWROW09?	NGPvVWFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NFq3V3YyQTR3OEO1PC=>
CAL62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\TPFAvOS1zMECgcm0>	M1;LeFczKGh?	NHHud2hFVVOR	MkXUSWM2OD1zLkSgcm0>	NITDRoQyQTJ{M{W1Ny=>
OCUT-1	M3;vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXv3dJhiOC5zLUGwNEBvVQ>?	M4TkXVczKGh?	NH:zSVVFVVOR	MYTFR\|UxRTJwMzDuUS=>	NXHtTFdCOTl{MkO1OVM>
8505C	NHmy[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOwNE4yNTFyMDDuUS=>	M{\DelczKGh?	MmfMSG1UVw>?	MoHhSWM2OD1\|LkKgcm0>	Ml7lNVkzOjN3NUO=
ACT-1	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7sNE4yNTFyMDDuUS=>	MX23NkBp	M{OyOGROW09?	NUXuVXBJTUN3ME21MlQhdk1?	M2fmW\|E6OjJ\|NUWz
SW1736	NUfCXmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HMVFAvOS1zMECgcm0>	NWjI[3BNPzJiaB?=	MX;EUXNQ	MX7FR\|UxRTVwNjDuUS=>	MlS4NVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research: ^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Volasertib induces cell cycle arrest and apoptosis in various cancer cells. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 (Ro5203280) is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
Onvansertib (NMS-P937)

Onvansertib (NMS-P937, PCM-075, NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536